email article
Bamlanivimab, the monoclonal antibody authorized to treat less-severe cases of COVID-19, reduced the risk of contracting symptomatic disease among nursing home residents and staff in the placebo-controlled BLAZE-2 trial, said manufacturer Eli Lilly on Thursday.
After 8 weeks of follow-up, incidence of symptomatic COVID-19 was significantly lower among all individuals receiving the drug compared with placebo (OR 0.43).
And a pre-specified group of nursing home residents had even lower odds of symptomatic disease than those in the control group (OR 0.20), the company said.
These results of the phase III BLAZE-2 trial were announced via press release. The trial was conducted in partnership with the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, and the COVID-19 Prevention Network. Lilly promised to submit the data for peer-reviewed publication and presentation at a future medical meeting.
After spending nearly two months at home due to an adjusted fall and spring academic calendar in light of the COVID-19 pandemic, some students may be feeling unmotivated to pick up their pencils and open their textbooks again as they’ve returned to Ball State’s campus this semester.
E-Mail
IMAGE: Researchers at Vanderbilt University Medical Center and colleagues have identified genetic factors that increase the risk for developing pneumonia and its severe, life-threatening consequences. view more
Credit: Vanderbilt University Medical Center
Researchers at Vanderbilt University Medical Center and colleagues have identified genetic factors that increase the risk for developing pneumonia and its severe, life-threatening consequences.
Their findings, published recently in the
American Journal of Human Genetics, may aid efforts to identify patients with COVID-19 at greatest risk for pneumonia, and enable earlier interventions to prevent severe illness and death.
Despite the increasing availability of COVID-19 vaccines, it will take months to inoculate enough people to bring the pandemic under control, experts predict. In the meantime, thousands of Americans are hospitalized and die from COVID-19 each day.
A study of nursing home residents found the monoclonal antibody treatment bamlanivimab cut the risk of COVID-19 by up to 80%, maker Eli Lilly announced.